Merck

Gate

2026-10-12 08:34:54

Gate completes USDT dividend payouts for 145 U.S. stocks and ETFs

Gate has completed cash dividend distributions for 145 U.S. stock and ETF underlyings, including Taiwan Semiconductor Manufacturing Co. (TSM), Merck (MRK), Salesforce (CRM), Altria (MO), the Invesco QQQ Trust (QQQ), and NXP Semiconductors (NXPI), according to an official company announcement cited by Odaily. The exchange said it settled the corresponding dividends in USDT based on users’ positions, with the full process handled automatically and no additional action required from users. The distribution covers eligible U.S. equity and ETF products with corporate payment dates running from Oct. 5, 2026 to Oct. 9, 2026. Gate said the covered names span a wide set of sectors, including technology and semiconductors, financial services, energy, consumer goods, healthcare, industrial manufacturing, real estate investment trusts, utilities, materials, media and entertainment, telecommunications, and strategy ETFs.

00

Moderna

2026-10-10 22:44:59

Moderna tops S&P 500 in 2026 with gains of more than 600%

Moderna, not an AI-linked chipmaker, has become the best-performing stock in the S&P 500 so far in 2026, according to Techub, citing BeInCrypto. The vaccine maker’s shares have climbed more than 600% this year and closed at $225 last Friday. The rally was tied to late-stage trial results for its experimental cancer vaccine. The surge also pushed Moderna back into the Nasdaq-100 Index. More than 200 funds tracking that benchmark, with over $800 billion in assets under management, are required to buy the stock. Moderna and Merck said on Aug. 19 that their experimental cancer vaccine passed a final-stage trial in melanoma patients, though detailed results have not yet been released. Investors are expected to get the full trial data on Oct. 24 at a major cancer conference in Madrid. Not everyone is convinced the move can hold. Former pharmaceutical executive Martin Shkreli said Moderna’s stock bubble could burst within the next six months.

100

Hedera

2026-09-08 09:48:46

The Hashgraph Group, Merck, and PwC Germany Pilot Hedera-Based Cocoa Traceability Solution

The Hashgraph Group, in collaboration with Merck and with advisory and implementation support from PwC Germany, is piloting a cocoa traceability solution that combines Merck's M-Trust physical authentication technology with a TrackTrace digital product passport platform built on the Hedera network. The system aims to verify cocoa origin, authenticity, quality, recall needs, and compliance data, targeting the EU's Deforestation Regulation (EUDR) requirements. The solution is designed to be scalable beyond cocoa to pharmaceuticals, luxury goods, and industrial components. According to Husen Kapasi, head of enterprise blockchain at PwC Germany, the solution offers verifiability that could be critical in food recalls or compliance investigations.

1050

cancer vaccin

2026-09-08 02:20:09

Tempus AI Could See Over $600M in Annual Revenue from Cancer Vaccine Sequencing, Analysts Say

Moderna and Merck's personalized cancer vaccines have added over $50 billion in market value to the two drugmakers. The diagnostic sequencing process behind these vaccines is emerging as a new investment opportunity. Tempus AI, as a sequencing partner for the Moderna-Merck vaccine, could benefit if the vaccine is approved. Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million in annual sequencing revenue, while BTIG analyst Mark Massaro projects the figure could exceed $600 million. The post-treatment cancer recurrence monitoring market via blood tests is seen as a multi-billion-dollar opportunity, but Natera currently dominates. However, uncertainties remain in the mRNA cancer vaccine field, and pharma companies may internalize some sequencing work in the future.

1110

Biotech

2026-08-26 01:46:35

Biotech shares rally across U.S. and Hong Kong as Moderna jumps 14% and CanSino rises more than 17%

Biotech stocks posted sharp gains across U.S. and Hong Kong markets on Aug. 26, according to market data cited by BlockBeats. Moderna (MRNA) closed up 14.36% in U.S. trading with turnover reaching $7.636 billion, while Merck (MRK) gained 3.84%. The move followed a recent joint announcement from Moderna and Merck that their first personalized mRNA cancer therapy, intismeran autogene, succeeded in a global Phase III clinical trial for high-risk melanoma. After that update, several major banks raised their price targets on Moderna, including Bank of America, Piper Sandler, Goldman Sachs, JPMorgan, and Barclays. In Hong Kong trading, CanSino Biologics rose 17% after the open, while Innovent Biologics gained more than 10%, Everest Medicines rose more than 7%, Akeso climbed more than 6%, and RemeGen advanced more than 4%. CanSino also said its subsidiary CanSino Shanghai had formally signed a strategic framework agreement with DeepVessel Biopharma to jointly develop and commercialize personalized therapeutic mRNA tumor vaccines.

1150

Stanford Univ

2026-08-22 22:25:29

Stanford study finds AI agent debate works best in specific settings, not every case

Researchers at Stanford University found that multi-agent systems built around structured debate can outperform other team-based strategies, including sequential chains and ensemble methods, on complex reasoning tasks. The result was not one-sided, though. The study also found that when a single agent is given the same compute budget as a multi-agent team, it can often match or even beat the multi-agent setup. The reported advantage for debate-based architectures was strongest in three cases: when the underlying model is relatively weak, when the input data is noisy or degraded, and when the task requires filtering large amounts of information. The team tested models including Qwen3-30B-A3B and Gemini 2.5 Flash. It also deployed 37,000 AI agents to design antibody-drug conjugates, a targeted cancer therapy that combines antibodies with chemotherapy drugs. According to the report, that design work was independently validated by Merck. The researchers added that information loss during handoffs between agents remains a key weakness of multi-agent systems, while single-agent setups are still the better option for frontier models working with structured data.

510

JPMorgan

2026-08-21 03:32:49

JPMorgan keeps bearish view on Moderna, says INT melanoma win was already priced in

JPMorgan said in an Aug. 19 research note that Moderna and Merck’s individualized neoantigen therapy, referred to as INT, met its primary endpoint in adjuvant melanoma, with recurrence-free survival showing a significant improvement. The key secondary endpoint, distant metastasis-free survival, also met the bar. Even so, the bank argued the result was widely expected and had already been reflected in Moderna’s share price before the update was released. The firm kept its Underweight rating and a $40 price target on Moderna, versus a current share price of $63 cited in the note, implying 36% downside. JPMorgan’s view is that the clinical success of INT in adjuvant melanoma is no longer the main valuation question. Instead, the next leg of value depends on whether the therapy can show similar efficacy across a broader set of tumor types. JPMorgan said it had already assigned an 85% probability of success to the phase III melanoma study, based on prior phase IIb data and the biological rationale of the approach in cancer immunotherapy. The bank added that adjuvant melanoma is a relatively small indication, and that Moderna’s roughly $25 billion market value already includes expectations for approval in this setting. It said future data in non-melanoma indications will be more important for the company’s valuation.

1180

Moderna

2026-08-21 02:05:21

Moderna melanoma Phase 3 readout puts AI-driven drug development deeper into clinical and manufacturing workflows

Moderna and Merck said on Aug. 19 that the Phase 3 INTerpath-001 trial delivered a positive topline readout in resected Stage IIB-IV melanoma, with Intismeran plus Keytruda showing statistically significant and clinically meaningful improvement in recurrence-free survival and distant metastasis-free survival versus Keytruda alone. The study enrolled 1,137 patients, but Moderna has not yet released the hazard ratios, absolute recurrence-rate differences, or overall survival data, so the only firm conclusion for now is that the Phase 3 study met its interim bar. The trial will continue rather than stop early. The report argues that the bigger story is operational. Intismeran is not a one-formula product for every patient. The therapy is built from each patient’s tumor and blood genetic information, with up to 34 neoantigens selected before a personalized mRNA treatment is produced. Moderna’s Maestro digital system coordinates clinical operations, manufacturing, quality control, and logistics across separate production batches. The article also points to upstream data work by Personalis, whose tumor analysis platform has been used by Moderna and Merck since the early V940/mRNA-4157 program, and notes Tempus AI’s planned acquisition of Personalis at about $1.5 billion enterprise value. It pairs that development with Anthropic’s recent protein-design experiment to show a broader shift: AI is moving out of stand-alone software and into real-world research, lab, production, and clinical processes.

1550